William E Haley1, Felicity T Enders2, Lisa E Vaughan2, Ramila A Mehta2, Maxton E Thoman1, Terri J Vrtiska3, Amy E Krambeck4, John C Lieske1, Andrew D Rule5. 1. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN. 2. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN. 3. Department of Radiology, Mayo Clinic, Rochester, MN. 4. Department of Urology, Mayo Clinic, Rochester, MN. 5. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN. Electronic address: Rule.andrew@mayo.edu.
Abstract
OBJECTIVE: To determine whether there is a persistent decline in kidney function after the first kidney stone event. PATIENT AND METHODS: Incident symptomatic stone formers and age- and sex-matched controls underwent 2 study visits 90 days apart to assess kidney function, complete a survey, and have their medical records reviewed. Kidney function was compared between stone formers and controls adjusting for clinical, blood, and urine risk factors. RESULTS: There were 384 stone formers and 457 controls. At visit 1, a median of 104 days after the stone event, stone formers compared with controls had similar serum creatinine (0.86 vs 0.84 mg/dL; P=.23), higher serum cystatin C (0.83 vs 0.72 mg/L; P<.001), higher urine protein (34.2 vs 19.7 mg/24 h; P<.001) levels, and were more likely to have albuminuria (24 h urine albumin >30 mg: 5.4% vs 2.2%; P=.02). Findings were similar after adjustment for risk factors and at visit 2, a median of 92 days after visit 1. In the 173 stone formers with serum creatinine levels from care before study participation, the mean serum creatinine level was 0.84 mg/dL before the stone event, increased to 0.97 mg/dL (P<.001) at the stone event, but returned to 0.85 mg/dL (P=.38) after the stone event (visit 1). CONCLUSIONS: Incident symptomatic stone formers have a rise in serum creatinine levels that resolves. However, stone formers have sustained higher cystatin C levels and proteinuria that may affect long-term risk of chronic kidney disease. Copyright Â
OBJECTIVE: To determine whether there is a persistent decline in kidney function after the first kidney stone event. PATIENT AND METHODS: Incident symptomatic stone formers and age- and sex-matched controls underwent 2 study visits 90 days apart to assess kidney function, complete a survey, and have their medical records reviewed. Kidney function was compared between stone formers and controls adjusting for clinical, blood, and urine risk factors. RESULTS: There were 384 stone formers and 457 controls. At visit 1, a median of 104 days after the stone event, stone formers compared with controls had similar serum creatinine (0.86 vs 0.84 mg/dL; P=.23), higher serum cystatin C (0.83 vs 0.72 mg/L; P<.001), higher urine protein (34.2 vs 19.7 mg/24 h; P<.001) levels, and were more likely to have albuminuria (24 h urine albumin >30 mg: 5.4% vs 2.2%; P=.02). Findings were similar after adjustment for risk factors and at visit 2, a median of 92 days after visit 1. In the 173 stone formers with serum creatinine levels from care before study participation, the mean serum creatinine level was 0.84 mg/dL before the stone event, increased to 0.97 mg/dL (P<.001) at the stone event, but returned to 0.85 mg/dL (P=.38) after the stone event (visit 1). CONCLUSIONS: Incident symptomatic stone formers have a rise in serum creatinine levels that resolves. However, stone formers have sustained higher cystatin C levels and proteinuria that may affect long-term risk of chronic kidney disease. Copyright Â
Authors: Michael G Shlipak; Kunihiro Matsushita; Johan Ärnlöv; Lesley A Inker; Ronit Katz; Kevan R Polkinghorne; Dietrich Rothenbacher; Mark J Sarnak; Brad C Astor; Josef Coresh; Andrew S Levey; Ron T Gansevoort Journal: N Engl J Med Date: 2013-09-05 Impact factor: 91.245
Authors: Ion D Bucaloiu; H Lester Kirchner; Evan R Norfolk; James E Hartle; Robert M Perkins Journal: Kidney Int Date: 2011-12-07 Impact factor: 10.612
Authors: Alexander P Reiner; Arnold Kahn; Brian H Eisner; Mark J Pletcher; Natalia Sadetsky; O Dale Williams; Joseph F Polak; David R Jacobs; Marshall L Stoller Journal: J Urol Date: 2011-01-19 Impact factor: 7.450
Authors: Ziad M El-Zoghby; John C Lieske; Robert N Foley; Eric J Bergstralh; Xujian Li; L Joseph Melton; Amy E Krambeck; Andrew D Rule Journal: Clin J Am Soc Nephrol Date: 2012-06-28 Impact factor: 8.237
Authors: Vincent Castiglione; Hans Pottel; John Charles Lieske; Pierre Lukas; Etienne Cavalier; Pierre Delanaye; Andrew David Rule Journal: J Nephrol Date: 2019-06-20 Impact factor: 3.902
Authors: Tsering Dhondup; Wonngarm Kittanamongkolchai; Lisa E Vaughan; Ramila A Mehta; Jasdeep K Chhina; Felicity T Enders; LaTonya J Hickson; John C Lieske; Andrew D Rule Journal: Am J Kidney Dis Date: 2018-08-23 Impact factor: 8.860